SFA Therapeutics, Inc. To Present At The Microbiome R&D and Business Collaboration Forum
Will Report on Clinical Development Plans for Multiple Promising Therapeutics Derived from Human Microbiome
PHILADELPHIA - Oct. 25, 2019 - PRLog -- SFA Therapeutics, Inc. announced today that Dr. Ira Spector, company CEO, will report on updates in the company's clinical development plans for several new therapeutic agents they have derived from the human microbiome. The presentation will be delivered as part of the Microbiome R&D and Business Collaboration Forum on October 29th at 5:45PM at the Paradise Point Resort & Spa in San Diego, CA.
About SFA Therapeutics
SFA Therapeutics, Inc. is a bio-pharmaceutical company focused on new human-microbiome-
SFA's small-molecule drugs are derived from natural substances produced in the human microbiome and enable a new platform for developing safer treatments for inflammatory diseases. SFA's drug development platform has been exclusively licensed from Temple University to SFA Therapeutics in Jenkintown, PA. Please visit www.sfatherapeutics.com to learn more.
Dr. Ira Spector, CEO